Rce Tanner et al, 202078 Imply (95 CI or SE)a 1 DNA Methyltransferase Formulation Distributiona,b NA Source NA, assumption according to lack of comparative long-term clinical dataOntario Health Technology Assessment Series; Vol. 21: No. 13, pp. 114, AugustAugustSensitivity Evaluation: Parameter Uncertainty Medication-Related TAM Receptor custom synthesis Disutility Parameter Disutility linked with medication unwanted side effects Disutility related with medication negative effects Cost of Testing Parameter Price of PGx: lower variety Cost of PGx: upper range Cost of PGx: threshold evaluation Imply (SE)a 2,500 (625)78 Distributiona,b Gamma Source Tanner et al, 202078 Tanner et al, 202078 Tanner et al, 202078 Imply (SE)a 450 (112.5) Distributiona,b Gamma Source Assumption on variety for this price was determined by Maruf et al, 2020,21 and Tanner et al78 Assumption on range for this cost was depending on Maruf et al, 2020,21 and Tanner et al78 Deterministic, one-way threshold evaluation Imply (SE)a -0.055 (0.03) Distributiona,b Beta Source Mrazek et al, 2013,109,110 Najafzadeh et al, 201781 Mrazek et al, 2013,109,110 Najafzadeh et al, 201781 Imply (95 CI or SE)a -0.01 (0.03) Distributiona,b Beta Source Revicki,Reference Case AnalysisSensitivity Analysis-0.055 (0.03)Beta-0.12 (0.03)BetaRevicki,two,500 (625)Gamma3,750 (937.5)Gamma2,500 (625)GammaNANANo. of Necessary Visits Using a Doctor or possibly a Well being Care Provider Throughout Testing Parameter Visits needed throughout testing Mean 2 Distributiona,b NA Supply Expert consultation Imply 0, 1, and 3 Distributiona,b NA Supply Expert consultation, 3 visits were assumed to accommodate pharmacists as another provider in circle of care or possibly a delay in receiving benefits of testOntario Well being Technology Assessment Series; Vol. 21: No. 13, pp. 114, AugustAugustSensitivity Analysis: Parameter UncertaintyReference Case AnalysisSensitivity AnalysisCosts of Prescription Drugs in Remission (2020 CAD) Parameter Medication fees, monthly (2020 CAD): initial 6 mo/Rest of follow-up (see Table six)c Medication expenses, monthly (2020 CAD): first six mo/Rest of follow-up (see Table 6)c Imply (SE)a 122.86 (0.58) /44.93 (0.29) Distributiona,b Gamma Source Tanner et al, 201987; Tanner et al, 202078 Tanner et al, 201987; Tanner et al, 202078 Mean (SE)a 122.86/mo Distributiona,b Gamma Supply Constant higher prescription drug costs more than 1-year time horizon; source for cost inputs was Tanner et al, 201987 Constant reduced prescription drug expenses more than 1-year time horizon; source for expense inputs was Tanner et al,122.86 (0.58) / 44.93 (0.29)Gamma44.93 (0.29)GammaCosts Linked With Overall health Care Service Use and Hospitalization in Remission (2020 CAD) Parameter Health care service and hospitalization costs, monthly (see Table six)c Imply (SE)a 145.02 (0.92) Distributiona,b Gamma Source Tanner et al, 201987; Tanner et al, 202078 Mean (SE)a 0 mo: 613.17 (7.58) 72 mo: 145.02 (0.92) 290.04 (0.92) Gamma Distributiona,b Gamma Source Time-dependent lower in overall health care spending (see Table 6) ; supply for cost inputs was Tanner et al, 201987 2x higher spending in remissionHealth care service and hospitalization charges, monthly (see Table six)c145.02 (0.92)GammaTanner et al, 201987; Tanner et al,Abbreviations: CI, self-confidence interval; NA, not applicable; PGx, multi-gene pharmacogenomic-guided therapy that involves a choice support tool; SE, regular error; TAU, remedy as usual. a Regular errors were estimated anytime information had been obtainable; SEs linked with relative risk of relapse was assumed to be ten of mean; SEs related with price tag.
